Filter
589
Text search:
variant
Featured
71
85
Language
Document type
176
145
142
35
28
27
17
6
6
5
1
1
Countries
28
26
24
21
14
13
12
12
11
10
9
8
7
7
7
7
7
7
6
6
6
5
5
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
239
37
20
19
13
12
6
1
Toolboxes
206
40
19
14
13
12
12
12
12
11
10
10
10
9
9
8
7
6
6
5
5
3
2
1
1
1
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been
...
Nature | Vol 600 | 2 December 2021 |
The 2021 COVID-19 Strategic Preparedness and Response Plan (SPRP) for AFR serves as a regional guide for a holistic public health response to COVID‑19 at regional, national and sub-national levels. The 2021
SPRP:
1. Builds upon the lessons learnt from the implementation of the 2020 SPRP and outl
...
New funding requirements: CHF 2.8 billion IFRC-wide of which CHF 670 million is channelled through the IFRC Emergency Appeal in support of National Societies
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
orientations provisoires, première publication le 25 janvier 2021, mise à jour le 15 juin 2021, mise à jour le 19 novembre 2021
Updated Treatment Guidelines
Natural immunity against COVID-19
Scientific report 10 May 2021
